Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550992 | 0.98 | FAAH (0.39) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL1012064 | 0.98 | FAAH (0.39) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL496169 | 0.98 | FAAH (0.39) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL8980908 | 0.98 | FAAH (0.39) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL8981350 | 0.98 | FAAH (0.39) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL202837 | 0.96 | BTK (0.38) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL142219 | 0.92 | MEN1 (0.39) | BTKMEN1KMT2AMAPK1GHSR | |
| SCHEMBL2789711 | 0.86 | GHSR (0.37) | BTKMEN1KMT2AMAPK1FAAH | |
| SCHEMBL18482795 | 0.86 | GAA (0.36) | BTKMEN1KMT2AMAPK1GHSR | |
| SCHEMBL2085827 | 0.86 | CXCR5 (0.40) | BTKMEN1KMT2AMAPK1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687951-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | Codexis, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2024196434-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CODEXIS, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240318152-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | CODEXIS, INC. | 2024-09-26 | — | — | US | claimed |
| CN-112876507-A | Trisubstituted olefin tertiary phosphine compound and preparation method thereof | 湖北大学 | 2021-06-01 | — | — | CN | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4687951-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | Codexis, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687951-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | Codexis, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| CN-120813367-A | P450-BM3 variants with improved activity | 科德克希思公司 | 2025-10-17 | — | — | CN | disclosed |
| US-5270331-A | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides | PFIZER, INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0504168-A4 | SYNTHETIC CALCITONIN PEPTIDES | — | 1993-09-22 | — | — | EP | disclosed |
| US-5175146-A | Improved potency; storage stability; nonhydrolyzing; osteoporosis; Paget's disease; hypocalcemic | VICAL, INC. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5162336-A | Disorders of gastrointestinal, central nervous and appetite regulatory systems | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0504168-A1 | SYNTHETIC CALCITONIN PEPTIDES | VICAL, INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0491943-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1992000295-A1 | TETRAHYDROPYRIDOINDOLES AS CHOLECYSTOKININ AND GASTRIN ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991007978-A1 | SYNTHETIC CALCITONIN PEPTIDES | VICAL, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | BTK 3996/4885MEN1 3795/4885KMT2A 3563/4885 |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | BTK 382/4885MEN1 1464/4885KMT2A 4273/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | BTK 2244/4885MEN1 4664/4885KMT2A 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.